| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/978-3-319-22542-5_7 |
| P698 | PubMed publication ID | 26494388 |
| P50 | author | Bruce Robinson | Q124029931 |
| P2093 | author name string | Diana L Learoyd | |
| Lyndal J Tacon | |||
| Venessa H M Tsang | |||
| P2860 | cites work | Germline mutations in TMEM127 confer susceptibility to pheochromocytoma | Q24299202 |
| A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas | Q24811594 | ||
| Management of the clinically inapparent adrenal mass ("incidentaloma") | Q28179984 | ||
| Activation of a novel human transforming gene, ret, by DNA rearrangement | Q28286635 | ||
| Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. | Q30320251 | ||
| Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma | Q33586665 | ||
| The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2 | Q33587939 | ||
| Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results | Q34203293 | ||
| Characterization of a multicomponent receptor for GDNF. | Q34383378 | ||
| Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma | Q34468665 | ||
| Germ-line mutations in nonsyndromic pheochromocytoma | Q34523021 | ||
| Posterior retroperitoneoscopic adrenalectomy is a safe and effective alternative to transabdominal laparoscopic adrenalectomy for pheochromocytoma | Q42614581 | ||
| A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines | Q44306785 | ||
| Expanding the indications for laparoscopic retroperitoneal adrenalectomy: experience with 81 resections | Q44645136 | ||
| Somatostatin Receptor Subtypes in Human Pheochromocytoma: Subcellular Expression Pattern and Functional Relevance for Octreotide Scintigraphy | Q44645510 | ||
| Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma | Q45219918 | ||
| Long-term outcomes of surgical treatment for hereditary pheochromocytoma | Q45334899 | ||
| Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study. | Q45748853 | ||
| Pheochromocytoma in MEN 2A syndrome. Study of 54 patients | Q45841606 | ||
| Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). | Q46092379 | ||
| Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma | Q46098827 | ||
| Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors | Q46239526 | ||
| Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma | Q46252973 | ||
| Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients | Q46379788 | ||
| Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. | Q46827190 | ||
| Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline | Q46897538 | ||
| Prognostic markers in pheochromocytoma. | Q50887149 | ||
| Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. | Q51872730 | ||
| Management and treatment of pheochromocytomas and paragangliomas. | Q53246827 | ||
| MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma | Q56964302 | ||
| Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre | Q57750208 | ||
| Somatostatin Receptor Imaging with68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation | Q57758753 | ||
| KI-67 AND hTERT Expression Can Aid in the Distinction between Malignant and Benign Pheochromocytoma and Paraganglioma | Q62554220 | ||
| Pheochromocytoma in multiple endocrine neoplasia type 2: European study | Q62978347 | ||
| Pulmonary oedema after propranolol therapy in two cases of phaeochromocytoma | Q67325216 | ||
| Treatment of malignant pheochromocytoma with combination chemotherapy | Q70110543 | ||
| Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2-relevance of specific mutations in the RET proto-oncogene | Q71540782 | ||
| Malignant phaeochromocytoma of the organ of Zuckerkandl with functioning metastases | Q72220999 | ||
| Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes | Q72221317 | ||
| Phaeochromocytoma: how to catch a moonbeam in your hand | Q73082404 | ||
| Tumor recurrence and hypertension persistence after successful pheochromocytoma operation | Q73336326 | ||
| Tumour angiogenesis and Ki-67 expression in phaeochromocytoma | Q73621743 | ||
| Nuclear Accumulation of B-Catenin in Human Endocrine Tumors: Association with Ki-67 (MIB-1) Proliferative Activity | Q74453834 | ||
| Increased expression of tenascin in pheochromocytomas correlates with malignancy | Q77089706 | ||
| Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases | Q78015705 | ||
| Pheochromocytoma penetrance varies by RET mutation in MEN 2A | Q80155293 | ||
| Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations | Q81604809 | ||
| Surgical management of organ-contained unilateral pheochromocytoma: comparative outcomes of laparoscopic and conventional open surgical procedures in a large single-institution series | Q82692876 | ||
| Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients | Q83159737 | ||
| Retroperitoneal laparoendoscopic single-site adrenalectomy for pheochromocytoma: our single center experiences | Q85634727 | ||
| Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDG PET/CT at initial diagnosis and 1-year follow-up | Q86716341 | ||
| Malignant pheochromocytoma: current status and initiatives for future progress | Q34550903 | ||
| Phaeochromocytomas presenting as acute crises after beta blockade therapy. | Q34569618 | ||
| Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location | Q34622491 | ||
| Preoperative management of the pheochromocytoma patient | Q34711597 | ||
| The management of benign and malignant pheochromocytoma and abdominal paraganglioma | Q35092215 | ||
| Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma | Q35190348 | ||
| Adrenal-preserving laparoscopic surgery in selected patients with bilateral adrenal tumors | Q35605414 | ||
| The genetic basis of pheochromocytoma. | Q35607347 | ||
| The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). | Q35607351 | ||
| Biochemical diagnosis of pheochromocytoma | Q35607354 | ||
| The clinically inapparent adrenal mass: update in diagnosis and management | Q35745002 | ||
| Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography | Q35925505 | ||
| Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. | Q35987855 | ||
| Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1. | Q36121940 | ||
| Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome | Q36463100 | ||
| An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges | Q36652761 | ||
| Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. | Q36688044 | ||
| Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment | Q36840180 | ||
| Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. | Q36932510 | ||
| The optimal imaging of adrenal tumours: a comparison of different methods | Q36959632 | ||
| Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience | Q37439075 | ||
| Medullary thyroid cancer: management guidelines of the American Thyroid Association | Q37495961 | ||
| Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease | Q37706151 | ||
| One Hundred Two Patients With Pheochromocytoma Treated at a Single Institution Since the Introduction of Laparoscopic Adrenalectomy | Q37790549 | ||
| AME position statement on adrenal incidentaloma. | Q37862478 | ||
| Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas | Q37951307 | ||
| An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. | Q37983510 | ||
| Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma | Q38077711 | ||
| Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity | Q38179962 | ||
| Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions | Q38217012 | ||
| Laboratory evaluation of pheochromocytoma and paraganglioma | Q38261645 | ||
| Paraganglioma and phaeochromocytoma: from genetics to personalized medicine | Q38266745 | ||
| Multidirectional differentiation in neuroendocrine neoplasms | Q40094808 | ||
| Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma | Q40562855 | ||
| Multiple endocrine neoplasia type 2. Clinical features and screening. | Q40624174 | ||
| Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. | Q40663240 | ||
| Clinical experience over 48 years with pheochromocytoma | Q40810053 | ||
| MEN type 2a presenting as an intra-abdominal emergency. | Q42055240 | ||
| P921 | main subject | phaeochromocytoma | Q536269 |
| multiple endocrine neoplasia | Q1553018 | ||
| P304 | page(s) | 157-178 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Recent Results in Cancer Research | Q26842185 |
| P1476 | title | Pheochromocytomas in Multiple Endocrine Neoplasia Type 2. | |
| P478 | volume | 204 |
| Q33702544 | Incidental Detection of Synchronous Medullary Thyroid Carcinoma with Bilateral Adrenal Pheochromocytoma on Iodine-123 Metaiodobenzylguanidine Scintigraphy, Leading to Diagnosis of Multiple Endocrine Neoplasia 2A |
| Q50203337 | Laparoscopic adrenalectomy as an effective approach to massive bilateral pheochromocytomas |
| Q39171991 | Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors |
Search more.